Xeno-free autologous cultivated limbal epithelial transplantation is effective

Article

Using xeno-free autologous cultivated limbal epithelial transplantation has proven to be effective in restoring corneal epithelial stability and improving vision in patients with ocular surface burns

Using xeno-free autologous cultivated limbal epithelial transplantation has proven to be effective in restoring corneal epithelial stability and improving vision in patients with ocular surface burns, according to a paper published in British Journal of Ophthalmology.

Dr Virender S. Sangwan et al., L V Prasad Eye Institute, Kallam Anji Reddy Campus, India, conducted a retrospective study on 200 patients with unilateral total limbal cell deficiency caused by ocular surface burns. Patients were treated between 2001 and 2010 and underwent a small limbal biopsy from the normal eye.

For 10 to 14 days limbal epithelial cells were expanded ex vivo on the human amniotic membrane. This was completed by using a xeno-free explant culture system. The patient's affected eye received cultured epithelial monolayer and amniotic membrane substrate transplantation. The outcome measures included postoperative corneal surface stability, visual improvement and complications.

Of the 200 eyes studied, 142 presented with a fully epithelised, avascular and clinically stable corneal surface with a mean follow-up of 3±1.6 years. In 121 eyes a two-line improvement in visual acuity was found.

The investigation has demonstrated the success of the limbal epithelial transplantation in restoring corneal epithelial stability in patients with ocular burns.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.